Dr. Dana Cardin
Claim this profileVanderbilt University/Ingram Cancer Center
Studies Pancreatic Cancer
Studies Stomach Cancer
8 reported clinical trials
17 drugs studied
Area of expertise
1Pancreatic Cancer
Stage IV
metastatic
locally advanced
2Stomach Cancer
Stage IV
metastatic
locally advanced
Affiliated Hospitals
Clinical Trials Dana Cardin is currently running
Pembrolizumab + Olaparib
for Pancreatic Cancer
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor proteins. These proteins help repair damaged deoxyribonucleic acid (DNA) and, therefore, play a role in ensuring the stability of each cell's genetic material. When either of these genes is mutated, or altered, such that its protein product is not made or does not function correctly, DNA damage may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to some types of cancer, including pancreatic cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Olaparib is an inhibitor of PARP, a protein that helps repair damaged DNA. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of pembrolizumab to the usual treatment of olaparib may help to shrink tumors in patients with metastatic pancreatic cancer with BRCA1 or BRCA2 mutations.
Recruiting1 award Phase 237 criteria
LY3962673
for Pancreatic Cancer
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Recruiting1 award Phase 14 criteria
More about Dana Cardin
Clinical Trial Related8 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Dana Cardin has experience with
- Gemcitabine Hydrochloride
- Olaparib
- Gemcitabine
- Nab-paclitaxel
- Dasatinib
- Erlotinib Hydrochloride
Breakdown of trials Dana Cardin has run
Pancreatic Cancer
Stomach Cancer
Pancreatic Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dana Cardin specialize in?
Dana Cardin focuses on Pancreatic Cancer and Stomach Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are metastatic.
Is Dana Cardin currently recruiting for clinical trials?
Yes, Dana Cardin is currently recruiting for 2 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Dana Cardin has studied deeply?
Yes, Dana Cardin has studied treatments such as Gemcitabine Hydrochloride, Olaparib, Gemcitabine.
What is the best way to schedule an appointment with Dana Cardin?
Apply for one of the trials that Dana Cardin is conducting.
What is the office address of Dana Cardin?
The office of Dana Cardin is located at: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University/Ingram Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.